Takahashi, T.; Ishida, K.; Emi, Y.; Sakamoto, M.; Imura, J.; Aishima, S.; Muro, K.; Uetake, H.; Oki, E.; Katayose, Y.;
et al. Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial. Cancers 2022, 14, 4392.
https://doi.org/10.3390/cancers14184392
AMA Style
Takahashi T, Ishida K, Emi Y, Sakamoto M, Imura J, Aishima S, Muro K, Uetake H, Oki E, Katayose Y,
et al. Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial. Cancers. 2022; 14(18):4392.
https://doi.org/10.3390/cancers14184392
Chicago/Turabian Style
Takahashi, Takao, Kazuyuki Ishida, Yasunori Emi, Michiie Sakamoto, Johji Imura, Shinichi Aishima, Kei Muro, Hiroyuki Uetake, Eiji Oki, Yu Katayose,
and et al. 2022. "Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial" Cancers 14, no. 18: 4392.
https://doi.org/10.3390/cancers14184392
APA Style
Takahashi, T., Ishida, K., Emi, Y., Sakamoto, M., Imura, J., Aishima, S., Muro, K., Uetake, H., Oki, E., Katayose, Y., Yoshida, K., Unno, M., Hyodo, I., Tomita, N., Sugihara, K., & Maehara, Y.
(2022). Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial. Cancers, 14(18), 4392.
https://doi.org/10.3390/cancers14184392